BMI Shouldn't Be the Only Way to Assess Who Can Access Weight-Loss Drugs

Research suggests that one in three Australian adults has a body-mass index (BMI) of 30 or above, and a further 34% has a BMI of 25 or above. Australia has approved weight-loss medications such as Wegovy and Mounjaro for use alongside a reduced-calorie diet and exercise, but these medications rely on BMI to determine eligibility. However, relying solely on BMI can be misleading, as it does not take into account factors such as muscle mass and overall health.

Key Takeaways:

• Around one in three Australian adults (32%) has a BMI of 30 or above, and a further 34% has a BMI of 25 or above.
• Australian authorities have approved weight-loss medications such as Wegovy and Mounjaro, but these medications rely on BMI to determine eligibility.
• BMI alone is not a reliable indicator of health status, as it can overestimate the risk of weight-related health problems and underestimate the risks for certain individuals.
• The international community is reconsidering the definition of obesity, moving away from relying solely on BMI, and toward a more comprehensive assessment of an individual's health.
• The Edmonton Obesity Staging System takes into account factors such as BMI, health conditions, physical function, and psychological symptoms to determine the level of obesity and potential health risks.
• Clinicians should consider individualized and evidence-based treatment, rather than solely relying on BMI to determine eligibility for weight-loss medications.
• Weight-loss medications should be used in conjunction with dietary changes, exercise, and other forms of support to achieve optimal health outcomes.
• A team of healthcare professionals, including a dietitian, exercise physiologist, psychologist, and GP, can provide comprehensive support for individuals with weight-related health issues.

Statistics:

• One in three Australian adults has a BMI of 30 or above
• A further 34% of Australian adults have a BMI of 25 or above
• Wegovy and Mounjaro medications reduce participants' body weight by up to 20% in trials
• Research suggests that medications can improve health outcomes and quality of life, but relying solely on BMI can be misleading.
• The Edmonton Obesity Staging System considers factors such as BMI, health conditions, physical function, and psychological symptoms to determine the level of obesity and potential health risks.

Sources:

• BMI shouldnt be the only way to assess who can access weight-loss drugs -- The Conversation
• doi.org.sdpl.idm.oclc.org/10.1016/S2213-8587(24)00316-4 -- International Committee for the Diagnosis of Obesity